OBJECTIVES

Present research entitled “Studies on Oral Bioavailability Enhancement of Lovastatin and establish In Silico Quantitative Structure Pharmacokinetic Relationships among Cardiovascular Drugs” has been envisaged to fulfill the following objectives:

1. To study In Vitro Oral Bioavailability Enhancement of Lovastatin by studying a few of the available bioavailability enhancement approaches. Lovastatin is a BCS class II drug and hence has a poor water solubility due to which its rate of solubilization is low. This drug has high permeability; therefore improvement in its solubility is expected to improve its bioavailability.

2. To establish In Silico Quantitative Structure Pharmacokinetic Relationships among Cardiovascular Drugs so that the involvement of animals, humans, wastage of money, etc. could be prevented on studies to be conducted on newly discovered cardiovascular drugs in future, as using this technique or establishing QSPkR among Cardiovascular drugs, we can predict Pharmacokinetic Parameters of the newly discovered cardiovascular drugs.

Hence, the important findings generated from present research being envisaged, can be evaluated for their utility in assessing new cardiovascular drugs that would fit pharmacokinetically in future successful clinical trials of new cardiovascular compounds.